DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $752,706 | -30.1% | 36,486 | 0.0% | 0.25% | -27.5% |
Q2 2023 | $1,076,702 | +28.1% | 36,486 | 0.0% | 0.34% | +23.0% |
Q1 2023 | $840,637 | +8.1% | 36,486 | +30.5% | 0.28% | +4.5% |
Q4 2022 | $777,762 | -9.4% | 27,967 | 0.0% | 0.27% | -15.8% |
Q3 2022 | $858,000 | +4.3% | 27,967 | 0.0% | 0.32% | +13.7% |
Q2 2022 | $823,000 | -8.6% | 27,967 | 0.0% | 0.28% | +6.9% |
Q1 2022 | $900,000 | -27.8% | 27,967 | 0.0% | 0.26% | -26.1% |
Q4 2021 | $1,247,000 | -11.6% | 27,967 | 0.0% | 0.35% | -18.3% |
Q3 2021 | $1,411,000 | -7.0% | 27,967 | +44.6% | 0.43% | -7.3% |
Q2 2021 | $1,518,000 | +8.8% | 19,346 | -20.8% | 0.46% | +1.1% |
Q1 2021 | $1,395,000 | -36.3% | 24,438 | -6.6% | 0.46% | -42.9% |
Q4 2020 | $2,190,000 | +188.9% | 26,151 | +23.6% | 0.81% | +147.2% |
Q3 2020 | $758,000 | +29.8% | 21,151 | -12.4% | 0.33% | +19.0% |
Q2 2020 | $584,000 | +38.1% | 24,151 | 0.0% | 0.27% | +17.1% |
Q1 2020 | $423,000 | – | 24,151 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |